Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.
Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
Medicare beneficiaries may pay less for 15 additional prescription drugs as early as 2027 as part of the next round of federal regulators' price negotiations with pharmaceutical manufacturers.
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback